NASDAQ:ARGS - Argos Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.16 -0.01 (-5.88 %)
(As of 05/22/2018 03:29 AM ET)
Previous Close$0.1750
Today's Range$0.1575 - $0.1750
52-Week Range$0.15 - $11.20
Volume38,082 shs
Average Volume765,562 shs
Market Capitalization$2.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53

About Argos Therapeutics (NASDAQ:ARGS)

Argos Therapeutics logoArgos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina.

Receive ARGS News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARGS
CUSIPN/A
Phone919-287-6300

Debt

Debt-to-Equity Ratio-1.31
Current Ratio1.80
Quick Ratio1.80

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.90 million
Price / Sales0.67
Cash FlowN/A
Price / CashN/A
Book Value($1.63) per share
Price / Book-0.10

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-40,570,000.00
Net Margins-2,135.68%
Return on EquityN/A
Return on Assets-171.85%

Miscellaneous

Employees39
Outstanding Shares7,910,000

Argos Therapeutics (NASDAQ:ARGS) Frequently Asked Questions

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS."

When did Argos Therapeutics' stock split? How did Argos Therapeutics' stock split work?

Shares of Argos Therapeutics reverse split on the morning of Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of Argos Therapeutics stock prior to the reverse split would have 5 shares after the split.

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc. (NASDAQ:ARGS) released its quarterly earnings data on Monday, April, 2nd. The biopharmaceutical company reported ($1.05) EPS for the quarter. The biopharmaceutical company had revenue of $1.67 million for the quarter. View Argos Therapeutics' Earnings History.

Who are some of Argos Therapeutics' key competitors?

Who are Argos Therapeutics' key executives?

Argos Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey D. Abbey, Pres, CEO & Director (Age 56)
  • Dr. Charles A. Nicolette Ph.D., Chief Scientific Officer and VP of R&D (Age 56)
  • Dr. Richard D. Katz, VP & CFO (Age 54)
  • Ms. Lori R. Harrelson CPA, VP of Fin. & Principal Accounting Officer (Age 49)
  • Mr. John D. Menditto, VP of Corp. Communications and Investor Relations

Has Argos Therapeutics been receiving favorable news coverage?

Media headlines about ARGS stock have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Argos Therapeutics earned a daily sentiment score of 0.05 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.02 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Argos Therapeutics?

Shares of ARGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Argos Therapeutics' stock price today?

One share of ARGS stock can currently be purchased for approximately $0.16.

How big of a company is Argos Therapeutics?

Argos Therapeutics has a market capitalization of $2.29 million and generates $1.90 million in revenue each year. Argos Therapeutics employs 39 workers across the globe.

How can I contact Argos Therapeutics?

Argos Therapeutics' mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The biopharmaceutical company can be reached via phone at 919-287-6300.


MarketBeat Community Rating for Argos Therapeutics (ARGS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about Argos Therapeutics and other stocks. Vote "Outperform" if you believe ARGS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Argos Therapeutics (NASDAQ:ARGS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AHoldHold
Consensus Rating Score: N/AN/A2.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$24.00$82.6667
Price Target Upside: N/AN/A206.83% upside956.85% upside

Argos Therapeutics (NASDAQ:ARGS) Consensus Price Target History

Price Target History for Argos Therapeutics (NASDAQ:ARGS)

Argos Therapeutics (NASDAQ:ARGS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2017FBR & CoLower Price TargetMkt Perform ➝ Mkt Perform$40.00 ➝ $24.00HighView Rating Details
3/17/2017Stifel NicolausLower Price TargetHold$24.00HighView Rating Details
2/22/2017Needham & Company LLCDowngradeBuy ➝ HoldN/AView Rating Details
2/22/2017JMP SecuritiesDowngradeOutperform ➝ Market PerformN/AView Rating Details
6/20/2016Piper Jaffray CompaniesReiterated RatingOverweight$220.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Argos Therapeutics (NASDAQ:ARGS) Earnings History and Estimates Chart

Earnings by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Argos Therapeutics (NASDAQ ARGS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/2/2018Q4 2017($1.05)$1.67 millionViewN/AView Earnings Details
11/9/2017Q3 2017($2.00)$0.05 millionViewN/AView Earnings Details
8/9/2017Q2 2017($4.50)($4.20)$0.10 million$0.07 millionViewN/AView Earnings Details
5/10/2017Q1 2017($11.60)$0.11 millionViewN/AView Earnings Details
3/16/2017Q4 2016($7.40)$0.16 millionViewN/AView Earnings Details
11/14/2016Q3 2016($7.00)($6.40)$0.35 million$0.15 millionViewN/AView Earnings Details
8/10/2016Q2($8.60)($9.60)$0.16 million$0.49 millionViewListenView Earnings Details
5/12/2016Q1($11.20)($11.40)$0.10 million$0.15 millionViewListenView Earnings Details
3/29/2016Q4($17.60)($16.80)$1.12 million$0.07 millionViewListenView Earnings Details
11/16/2015Q315($18.40)($19.40)$0.12 million$0.16 millionViewListenView Earnings Details
8/12/2015Q215($16.00)($19.00)$1.32 million$0.11 millionViewListenView Earnings Details
5/14/2015Q115($16.20)($17.80)$0.40 million$0.18 millionViewListenView Earnings Details
3/30/2015Q314($15.60)($16.60)$0.62 million$0.30 millionViewN/AView Earnings Details
11/13/2014Q3 2014($13.00)($15.40)$0.80 million$0.40 millionViewN/AView Earnings Details
8/13/2014Q214($12.00)($12.20)$1.27 million$1.26 millionViewN/AView Earnings Details
5/13/2014Q114($10.80)($21.00)$1.26 million$0.7988 millionViewN/AView Earnings Details
3/27/2014Q4 2013($68.40)($723.80)$2.60 million$0.72 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Argos Therapeutics (NASDAQ:ARGS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Argos Therapeutics (NASDAQ ARGS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.21%
Insider Trading History for Argos Therapeutics (NASDAQ:ARGS)
Institutional Ownership by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Argos Therapeutics (NASDAQ ARGS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2018Jeffrey D AbbeyCEOSell124,987$0.16$19,997.92510,046View SEC Filing  
1/9/2018Charles A NicoletteInsiderSell100,250$0.16$16,040.00View SEC Filing  
1/9/2018Richard D KatzVPSell104,435$0.16$16,709.60193,959View SEC Filing  
1/3/2018Charles A NicoletteInsiderSell92,001$0.16$14,720.16View SEC Filing  
1/3/2018Jeffrey D AbbeyCEOSell114,702$0.16$18,352.32635,033View SEC Filing  
1/3/2018Lori R HarrelsonVPSell59,072$0.16$9,451.52295,310View SEC Filing  
1/3/2018Richard D KatzCFOSell101,228$0.16$16,196.48298,394View SEC Filing  
10/7/2016International S PharmstandardMajor ShareholderBuy31,704$4.73$149,959.92View SEC Filing  
9/29/2016International S PharmstandardMajor ShareholderBuy43,618$4.56$198,898.08View SEC Filing  
9/20/2016International S PharmstandardMajor ShareholderBuy41,259$4.77$196,805.43View SEC Filing  
9/19/2016International S PharmstandardMajor ShareholderBuy5,580$4.76$26,560.80View SEC Filing  
9/16/2016International S PharmstandardMajor ShareholderBuy52,512$4.77$250,482.24View SEC Filing  
9/1/2016International S PharmstandardMajor ShareholderBuy16,977$4.78$81,150.06View SEC Filing  
8/24/2016International S PharmstandardMajor ShareholderBuy67,371$4.52$304,516.92View SEC Filing  
8/22/2016International S PharmstandardMajor ShareholderBuy75,474$4.24$320,009.76View SEC Filing  
12/16/2015Andrei Vladimirovich PetrovDirectorBuy5,000$1.80$9,000.005,000View SEC Filing  
12/16/2015Joan WinterbottomInsiderBuy250$1.83$457.50View SEC Filing  
12/15/2015Alexey Alexandrovic VinogradovDirectorBuy2,000$2.15$4,300.002,000View SEC Filing  
12/2/2015Jeffrey D AbbeyCEOBuy1,000$3.89$3,890.006,293View SEC Filing  
11/24/2015Holle Philippe Marie Marce VanDirectorBuy10,000$4.28$42,800.0045,100View SEC Filing  
9/3/2015Holle Philippe Marie Marce VanDirectorBuy12,000$6.27$75,240.0025,100View SEC Filing  
9/1/2015Holle Philippe Marie Marce VanDirectorBuy5,000$6.26$31,300.0013,100View SEC Filing  
8/25/2015Jean LamarreDirectorBuy2,500$6.14$15,350.002,500View SEC Filing  
8/19/2015Jeffrey D AbbeyCEOBuy5,500$4.75$26,125.00View SEC Filing  
2/12/2014Deventer Sander VanDirectorBuy36,416$8.00$291,328.00View SEC Filing  
2/12/2014International S PharmstandardMajor ShareholderBuy1,275,000$8.00$10,200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Argos Therapeutics (NASDAQ ARGS) News Headlines

Source:
DateHeadline
Free Stock Performance Review on Array BioPharma and Three More Biotech IndustryFree Stock Performance Review on Array BioPharma and Three More Biotech Industry
finance.yahoo.com - May 16 at 8:28 AM
Factors of Influence in 2018, Key Indicators and Opportunity within Bottomline Technologies, SkyWest, Pacific Biosciences of California, Argos Therapeutics, Luminex, and Fiserv — New Research Emphasizes Economic GrowthFactors of Influence in 2018, Key Indicators and Opportunity within Bottomline Technologies, SkyWest, Pacific Biosciences of California, Argos Therapeutics, Luminex, and Fiserv — New Research Emphasizes Economic Growth
finance.yahoo.com - April 27 at 8:35 AM
Form 4 ARGOS THERAPEUTICS INC For: Apr 25 Filed by: Abbey Jeffrey DForm 4 ARGOS THERAPEUTICS INC For: Apr 25 Filed by: Abbey Jeffrey D
www.streetinsider.com - April 26 at 5:13 PM
BRIEF-Argos Therapeutics Says Nasdaq To Delist Cos SharesBRIEF-Argos Therapeutics Says Nasdaq To Delist Co's Shares
www.reuters.com - April 26 at 5:13 PM
3 Things In Biotech, April 21: Solid Stands, Argos Stops, NewLink Strives3 Things In Biotech, April 21: Solid Stands, Argos Stops, NewLink Strives
seekingalpha.com - April 22 at 6:30 PM
Argos Therapeutics bails on late-stage study of Rocapuldencel-T in kidney cancer; shares down 64%Argos Therapeutics bails on late-stage study of Rocapuldencel-T in kidney cancer; shares down 64%
seekingalpha.com - April 20 at 8:31 AM
Argos Therapeutics (ARGS) to Discontinue ADAPT Trial; to Explore Strategic AlternativesArgos Therapeutics (ARGS) to Discontinue ADAPT Trial; to Explore Strategic Alternatives
www.streetinsider.com - April 20 at 8:31 AM
Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic ...Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic ...
globenewswire.com - April 19 at 5:34 PM
BRIEF-Argos Therapeutics Reports Results Of Interim Analysis Of The Adapt Trial And Announces Review Of Strategic ...BRIEF-Argos Therapeutics Reports Results Of Interim Analysis Of The Adapt Trial And Announces Review Of Strategic ...
www.reuters.com - April 19 at 5:34 PM
Argos To Terminate ADAPT Study; Plans To Explore Strategic AlternativesArgos To Terminate ADAPT Study; Plans To Explore Strategic Alternatives
www.nasdaq.com - April 19 at 8:22 AM
Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic AlternativesArgos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives
finance.yahoo.com - April 19 at 8:22 AM
Today’s Research Reports on Trending Tickers: Argos Therapeutics and Bellicum PharmaceuticalsToday’s Research Reports on Trending Tickers: Argos Therapeutics and Bellicum Pharmaceuticals
finance.yahoo.com - April 12 at 8:48 AM
Free Research Reports on These Biotech Stocks -- Omeros, Argos Therapeutics, Array BioPharma, and Aurinia PharmaFree Research Reports on These Biotech Stocks -- Omeros, Argos Therapeutics, Array BioPharma, and Aurinia Pharma
www.bizjournals.com - April 4 at 8:28 AM
Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational HighlightsArgos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
finance.yahoo.com - April 2 at 5:21 PM
Argos Therapeutics reports 4Q lossArgos Therapeutics reports 4Q loss
finance.yahoo.com - April 2 at 5:21 PM
Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018
finance.yahoo.com - March 28 at 5:13 PM
Argos Therapeutics (ARGS) Upgraded at ValuEngineArgos Therapeutics (ARGS) Upgraded at ValuEngine
www.americanbankingnews.com - March 25 at 8:45 PM
Detailed Research: Economic Perspectives on Navigant Consulting, CalAmp, Sonoco Products, Argos Therapeutics, K2M Group, and Altra Industrial Motion — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on Navigant Consulting, CalAmp, Sonoco Products, Argos Therapeutics, K2M Group, and Altra Industrial Motion — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - March 1 at 8:20 AM
Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV ImmunotherapyArgos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy
finance.yahoo.com - February 15 at 8:40 AM
A Daytraders Guide To FearA Daytrader's Guide To Fear
finance.yahoo.com - February 13 at 9:56 AM
Argos Therapeutics Inc (ARGS) Given Consensus Recommendation of "Hold" by BrokeragesArgos Therapeutics Inc (ARGS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 1:36 AM
Where Argos Therapeutics Inc (NASDAQ:ARGS) Stands In Terms Of Earnings Growth Against Its IndustryWhere Argos Therapeutics Inc (NASDAQ:ARGS) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - January 31 at 10:17 AM
34 Biggest Movers From Friday - Benzinga34 Biggest Movers From Friday - Benzinga
www.benzinga.com - January 22 at 8:05 AM
Argos executes reverse stock splitArgos executes reverse stock split
finance.yahoo.com - January 19 at 3:43 PM
Argos Therapeutics (ARGS) Planes 1-for-20 Reverse Stock SplitArgos Therapeutics (ARGS) Planes 1-for-20 Reverse Stock Split
www.streetinsider.com - January 19 at 12:26 PM
Argos Therapeutics Inc (ARGS) Insider Charles A. Nicolette Sells 100,250 SharesArgos Therapeutics Inc (ARGS) Insider Charles A. Nicolette Sells 100,250 Shares
www.americanbankingnews.com - January 12 at 3:24 PM
Argos Therapeutics Inc (ARGS) CEO Sells $19,997.92 in StockArgos Therapeutics Inc (ARGS) CEO Sells $19,997.92 in Stock
www.americanbankingnews.com - January 12 at 3:24 PM
Richard D. Katz Sells 104,435 Shares of Argos Therapeutics Inc (ARGS) StockRichard D. Katz Sells 104,435 Shares of Argos Therapeutics Inc (ARGS) Stock
www.americanbankingnews.com - January 12 at 3:24 PM
Insider Selling: Argos Therapeutics Inc (ARGS) Insider Sells 92,001 Shares of StockInsider Selling: Argos Therapeutics Inc (ARGS) Insider Sells 92,001 Shares of Stock
www.americanbankingnews.com - January 5 at 3:14 PM
Richard D. Katz Sells 101,228 Shares of Argos Therapeutics Inc (ARGS) StockRichard D. Katz Sells 101,228 Shares of Argos Therapeutics Inc (ARGS) Stock
www.americanbankingnews.com - January 5 at 3:14 PM
Jeffrey D. Abbey Sells 114,702 Shares of Argos Therapeutics Inc (ARGS) StockJeffrey D. Abbey Sells 114,702 Shares of Argos Therapeutics Inc (ARGS) Stock
www.americanbankingnews.com - January 5 at 12:08 PM
Comparing Argos Therapeutics (ARGS) and ChemoCentryx (CCXI)Comparing Argos Therapeutics (ARGS) and ChemoCentryx (CCXI)
www.americanbankingnews.com - December 29 at 5:28 PM
Should You Worry About Argos Therapeutics Inc’s (NASDAQ:ARGS) CEO Pay?Should You Worry About Argos Therapeutics Inc’s (NASDAQ:ARGS) CEO Pay?
finance.yahoo.com - December 29 at 3:34 PM
ETFs with exposure to Argos Therapeutics, Inc. : December 22, 2017ETFs with exposure to Argos Therapeutics, Inc. : December 22, 2017
finance.yahoo.com - December 22 at 11:40 AM
One Thing To Consider Before Buying Argos Therapeutics Inc (NASDAQ:ARGS)One Thing To Consider Before Buying Argos Therapeutics Inc (NASDAQ:ARGS)
finance.yahoo.com - December 14 at 11:42 AM
Argos Therapeutics, Inc. (ARGS) Short Interest Down 41.4% in NovemberArgos Therapeutics, Inc. (ARGS) Short Interest Down 41.4% in November
www.americanbankingnews.com - December 14 at 3:10 AM
ETFs with exposure to Argos Therapeutics, Inc. : December 11, 2017ETFs with exposure to Argos Therapeutics, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:33 PM
With 42.3% Earnings Growth Lately, Did Argos Therapeutics Inc (ARGS) Outperform The Industry?With 42.3% Earnings Growth Lately, Did Argos Therapeutics Inc (ARGS) Outperform The Industry?
finance.yahoo.com - December 5 at 11:48 AM
ETFs with exposure to Argos Therapeutics, Inc. : November 30, 2017ETFs with exposure to Argos Therapeutics, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:33 PM
Argos Provides Financial Update - GlobeNewswire (press release)Argos Provides Financial Update - GlobeNewswire (press release)
globenewswire.com - November 28 at 8:07 AM
Ocera Therapeutics (OCRX) and Argos Therapeutics (ARGS) Critical ComparisonOcera Therapeutics (OCRX) and Argos Therapeutics (ARGS) Critical Comparison
www.americanbankingnews.com - November 27 at 4:28 PM
Argos Therapeutics (ARGS) & The Competition Critical ReviewArgos Therapeutics (ARGS) & The Competition Critical Review
www.americanbankingnews.com - November 25 at 11:32 AM
Argos Therapeutics (ARGS) CEO Jeff Abbey on Q3 2016 Results - Earnings Call Transcript - Seeking AlphaArgos Therapeutics' (ARGS) CEO Jeff Abbey on Q3 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 15 at 2:33 AM
Argos Therapeutics (ARGS) Announces Update on Immunology Data from the Phase 3 ADAPT TrialArgos Therapeutics (ARGS) Announces Update on Immunology Data from the Phase 3 ADAPT Trial
www.streetinsider.com - November 14 at 2:13 AM
Edited Transcript of ARGS earnings conference call or presentation 13-Nov-17 1:30pm GMTEdited Transcript of ARGS earnings conference call or presentation 13-Nov-17 1:30pm GMT
finance.yahoo.com - November 14 at 2:13 AM
Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual MeetingArgos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting
finance.yahoo.com - November 11 at 9:32 AM
Short Interest in Argos Therapeutics, Inc. (ARGS) Rises By 106.7%Short Interest in Argos Therapeutics, Inc. (ARGS) Rises By 106.7%
www.americanbankingnews.com - November 11 at 3:40 AM
Argos Therapeutics reports 3Q lossArgos Therapeutics reports 3Q loss
finance.yahoo.com - November 10 at 1:49 PM
Argos Reports Third Quarter 2017 Financial Results and Operational Highlights - GlobeNewswire (press release)Argos Reports Third Quarter 2017 Financial Results and Operational Highlights - GlobeNewswire (press release)
globenewswire.com - November 9 at 5:13 PM
Comparing Argos Therapeutics (ARGS) and Its RivalsComparing Argos Therapeutics (ARGS) and Its Rivals
www.americanbankingnews.com - November 7 at 2:06 PM

SEC Filings

Argos Therapeutics (NASDAQ:ARGS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Argos Therapeutics (NASDAQ:ARGS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Argos Therapeutics (NASDAQ ARGS) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.